Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
Description
CONCLUSIONS: The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir-ritonavir and those who received placebo. (Supported by Pfizer; EPIC-SR ClinicalTrials
